Compare Riot Platforms Inc (RIOT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Riot Platforms Inc vs Recursion Pharmaceuticals Inc — how do they compare? Riot Platforms Inc trades at $16.9 (market cap $6.32B), while Recursion Pharmaceuticals Inc trades at $4.26 (market cap $2.14B). The key difference: Riot Platforms Inc is far larger — about 3× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is more actively traded (30,789,535 versus 30,571,756). Which is the better fit depends on your goals — on Pluang, investors hold Riot Platforms Inc for 16 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| RIOT | RXRX | |
|---|---|---|
Market Cap | $6.32B | $2.14B |
Volume | 30,571,756 | 30,789,535 |
Sector | Financials | Health |
52-Week High | $28.67 | $6.79 |
52-Week Low | $11.83 | $2.84 |
Typical Hold Time | 16 Days | 22 Days |
Enterprise Value | $6.73B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RIOT stock trades at $16.69, down 9.98% with bearish technical signals despite strong analyst support. The company shows concerning fundamentals with negative net income margins (-196.28%) and ROE (-48.24%), though revenue reached $647.44M in 2025. Recent strategic shift to data center services with $9.8B in contracted lease revenue through 2048 provides long-term visibility.
While analyst consensus remains strongly bullish (94.74% buy ratings) with $31.64 price target, execution risks persist given consecutive earnings misses and negative cash flow. The AI infrastructure pivot offers growth potential but requires careful monitoring of profitability improvements and Bitcoin market volatility exposure.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
